Skip to main content

Advertisement

SpringerLink
Log in

Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Background

The prognostic significance of anti-53 autoantibody in colorectal cancer (CRC) patients is unclear due to measurement of overall rather than disease-specific survival and generally short follow-up periods in many studies. We aim to investigate prognostic significance of anti-p53 auto-antibodies in a study with long-term follow-up (minimum 5 years).

Methods

ELISA for anti-p53 autoantibody was assayed in serum from 92 patients with CRC and 28 controls.

Results

Anti-p53 autoantibody was found in 20 patients (21.7%) and none of the controls. No difference in Dukes’ (A/B vs. C/D), Stage (I/II vs. III/IV), T1/2 vs. T3/4, N0 vs. N1/2, M0 vs. M1, poor vs. well/moderate differentiation and proximal vs. distal CRC was observed. Median overall survival was 62 months and median disease-specific survival was 73 months. Dukes’ C/D, Stage III/IV, N1/2 and M1 were associated with poor disease-specific survival in univariate analysis. Stage III/IV was an independent prognostic factor in overall and disease-free survival in multivariate analysis. Anti-p53 autoantibody sero-positivity did not influence overall (p = 0.980) or disease-specific survival (p = 0.874). Median overall survival in anti-p53 autoantibody positive patients was 62 months vs. 60 months in anti-53 autoantibody negative patients. Median disease-specific survival in anti-p53 autoantibody positive patients was 73 months vs. 82 months.

Conclusion

Anti-p53 autoantibody is not related to clinical parameters of CRC and has no prognostic significance in long-term follow-up.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Crawford LV, Pim DC, Bulbrook RD (1982) Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30:403–408

    Article  PubMed  CAS  Google Scholar 

  2. Soussi T (2000) p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60:1777–1788

    PubMed  CAS  Google Scholar 

  3. Tang R, Ko MC, Wang JY, Changchien CR, Chen HH, Chen JS, Hsu KC, Chiang JM, Hsieh LL (2001) Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int J Cancer 94:859–863

    Article  PubMed  CAS  Google Scholar 

  4. Kressner U, Inganas M, Byding S, Blikstad I, Pahlman L, Glimelius B, Lindmark G (1997) Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 17:593–599

    Google Scholar 

  5. Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR, Goh HS, Joseph D, Iacopetta B (2000) Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 36:2053–2060

    Article  PubMed  CAS  Google Scholar 

  6. Houbiers JG, van der Burg SH, van de Watering LM, Tollenaar RA, Brand A, van de Velde CJ, Melief CJ (1995) Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 72:637–641

    PubMed  CAS  Google Scholar 

  7. Kressner U, Glimelius B, Bergstrom R, Pahlman L, Larsson A, Lindmark G (1998) Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer 77:1848–1851

    PubMed  CAS  Google Scholar 

  8. Shiota G, Ishida M, Noguchi N, Oyama K, Takano Y, Okubo M, Katayama S, Tomie Y, Harada K, Hori K, Ashida K, Kishimoto Y, Hosoda A, Suou T, Kanbe T, Tanaka K, Nosaka K, Tanida O, Kojo H, Miura K, Ito H, Kaibara N, Kawasaki H (2000) Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival. Dig Dis Sci 45:122–128

    Article  PubMed  CAS  Google Scholar 

  9. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS (1994) Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58:480–487

    Article  PubMed  CAS  Google Scholar 

  10. Angelopoulou K, Stratis M, Diamandis EP (1997) Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer 70:46–51

    Article  PubMed  CAS  Google Scholar 

  11. Takeda A, Shimada H, Nakajima K, Yoshimura S, Suzuki T, Asano T, Ochiai T, Isono K (2001) Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection. Int J Clin Oncol 6:45–49

    Article  PubMed  CAS  Google Scholar 

  12. Shibata Y, Kotanagi H, Andoh H, Koyama K, Itoh H, Kudo S (1996) Detection of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody’s relation to clinical factors. Dis Colon Rectum 39:1269–1274

    Article  PubMed  CAS  Google Scholar 

  13. Bielicki D, Karbowniczek M, Sulzyc-Bielicka V, Kladny J, Boer C, Marlicz K, Domagala W (1999) Clinico-pathological characteristics of colorectal cancer and serum anti-p53 antibodies. Pol J Pathol 50:77–81

    PubMed  CAS  Google Scholar 

  14. Chang SC, Lin JK, Lin TC, Liang WY (2005) Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Int J Oncol 26:65–75

    PubMed  CAS  Google Scholar 

  15. Lechpammer M, Lukac J, Lechpammer S, Kovacevic D, Loda M, Kusic Z (2004) Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis 19:114–120

    Article  PubMed  Google Scholar 

  16. Broll R, Duchrow M, Oevermann E, Wellm C, Schwandner O, Schimmelpenning H, Roblick UJ, Bruch HP, Windhovel U (2001) p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue. Int J Colorectal Dis 16:22–27

    Article  PubMed  CAS  Google Scholar 

  17. Shimada H, Ochiai T, Nomura F (2003) Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer 97:682–689

    Article  PubMed  Google Scholar 

  18. Hammel P, Boissier B, Chaumette MT, Piedbois P, Rotman N, Kouyoumdjian JC, Lubin R, Delchier JC, Soussi T (1997) Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 40:356–361

    PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The authors would like to thank Rachel Waddington-Clark, ANR Statistical Consultants, for her aid in statistical analysis

Author information

Authors and Affiliations

  1. Cancer Division, Postgraduate Medical Institute, University of Hull, Wolfson Building, Hull, HU6 7RX, UK

    A. Suppiah, A. Alabi, L. Madden, J. E. Hartley, J. R. T. Monson & J. Greenman

Authors
  1. A. Suppiah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Alabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Madden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. E. Hartley
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. R. T. Monson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Greenman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Greenman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Suppiah, A., Alabi, A., Madden, L. et al. Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up. Int J Colorectal Dis 23, 595–600 (2008). https://doi.org/10.1007/s00384-008-0458-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-008-0458-4

Keywords

Search

Navigation